New Test May Reduce Need For Some Prostate Cancer Biopsies

A new prostate specific antigen (PSA) test that measures the percentage of "free" PSA in the blood not bound to other proteins could spare up to 200,000 men a year in the United States the pain, anxiety and inconvenience of a surgical biopsy to detect cancer.

Results of multicenter trials of the test, funded by its makers, Hybritech Inc., of San Diego, Calif., (a subsidiary of Beckman-Coulter Inc.), appear in the May 20 issue of the Journal of the American Medical Association.

According to Alan Partin, M.D., associate professor of urology at Johns Hopkins, one of the several centers involved in the trials, the new test should only apply to men whose prostates feel normal on digital rectal exams, but whose standard PSA levels are elevated and between four and 10. "These are the men in the diagnostic gray zone. They're at risk for prostate cancer on the basis of the PSA levels, but experience shows that 75 percent of the time, their biopsies will be negative for cancer," he says. The researchers were led by William J. Catalona, M.D., of Washington University School of Medicine (St. Louis, Mo.).

The test measures a form of PSA, called free PSA, that is lower in men with cancer than in those without cancer or with benign prostate enlargement, says Partin. "Now we can figure with more accuracy who not to biopsy," he says. In the past, he adds, using the percentage of free PSA (%FPSA) to determine risk was clouded by such factors as prostate size and the total amount of PSA.

"The study demonstrated that men in the diagnostic gray zone should probably be biopsied only if their %FPSA is at or below 25 percent. At that level, we can detect 95 percent of cancers while excusing men with benign diseases from the need for a biopsy," Partin says.

Prostate cancer screening tests, Partin says, must be sensitive enough to find as many potentially curable cancers as possible, even if they fail to detect microsco

Contact: Marc Kusinitz
Johns Hopkins Medical Institutions

Page: 1 2 3

Related biology news :

1. Reduced daily eye patching effectively treats lazy eye
2. Reduced-calorie diet adds nearly two years to dogs life span
3. Reduce calories, stave off hunger with water-rich foods -- not water
4. Zinc Reduces Child Mortality By More Than 34%
5. Dietary Carotenoid Lutein Reduces Atherosclerotic Lesion Formation In Mice
6. Residential Dust Control Fails To Reduce Blood Lead Levels In Children
7. Degrading Plastics To Reduce Waste
8. UF Researchers Show Common Compound Can Reduce Air Pollution
9. Plant-Based Fat May Reduce Risk Of Prostate Cancer By Altering Testosterone Metabolism, UB Study Shows
10. H Pylori Screening To Reduce The Risk Of Gastric Cancer
11. Technology Reduces Reliance On Fungicides For Grape Growers

Post Your Comments:

(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. While ... global economic downturn will only increase price pressures overall for the industry. The era ... from every product launch is critical. However, history shows that only a third of ...
(Date:7/10/2020)... , ... July 09, 2020 , ... Today CJ BIO ... which will share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, ... Umami Advantage will be live on Monday, July 13, 2020 at11:00 AM (CDT) during ...
(Date:7/2/2020)... ... 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , a ... for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology Association ... of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 single ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health ... growth, , Known as MediVet Biologics since its formation in ... The new Ardent Animal Health will build on its base of innovative therapies ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, Inc. (Nasdaq: ... advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ... strategic partnership whereby Catalent will provide support for the development, manufacturing, and clinical ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... After research ... The completion of a great surgery is only the beginning of a successful study, ... research community. , Join Brad Gien, Global Head of Surgery from Envigo ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... announced today that Massachusetts Institute of Technology (MIT) has expanded the company’s ... allows PathSensors to move into the point-of-care diagnostic market, focusing initially on ...
Breaking Biology Technology:
Cached News: